Efficacy and safety of Tribulus teresteris in female sexual disorder

Efficacy of Tribulus Teresteris in female sexual disorder in reproductive ages

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012111111425N1

Enrollment

Registered

2012-12-03

Start date

2012-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female sexual disease. Sexual dysfunction not caused by organic disorder or disease

Interventions

Intervention 1: In the drug group: a syrup from Tribulus extract, 7.5 cc, twice a day for 1 week. Intervention 2: In control group:A placebo syrup, 7.5 cc, twice a day, for 1 week.

Treatment - Drugs

In the drug group: a syrup from Tribulus extract, 7.5 cc, twice a day for 1 week

In control group:A placebo syrup, 7.5 cc, twice a day, for 1 week

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Fixed partner; Persistent or intermittent low libido; A normal pelvic examination; A normal pap smear; A normal breast examination. Exclusion criteria: No fixed partner; A serious medical situation; History of genital or breast cancer; An under observed depression or other psychological disorders

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Libido. Timepoint: At the begining of the trial, 7th day and one month after end of the drug. Method of measurement: FSFI questionaire.	—

Secondary

Measure	Time frame
Arousal. Timepoint: At the beginning of the study, 7 days after starting the drug and one month after finishing the drug. Method of measurement: FSFI questionnaire.;Desire. Timepoint: In the beginning of study, 7 days after it and 1 month after finishing the drug. Method of measurement: FSFI questionnaire.;Satisfaction. Timepoint: At the beginning of the study, 7days after it and 1 month after finishing the drug. Method of measurement: FSFI questionnaire.;Orgasm. Timepoint: At the beginning of the study, 7 days after it and 1 month after finishing the drug. Method of measurement: FSFI questionnaire.;Dysparonia. Timepoint: At the beginning of the study, 7 days after it and 1 month after finishing the drug. Method of measurement: FSFI questonnaire.	—

Measure

Time frame

Arousal. Timepoint: At the beginning of the study, 7 days after starting the drug and one month after finishing the drug. Method of measurement: FSFI questionnaire.;Desire. Timepoint: In the beginning of study, 7 days after it and 1 month after finishing the drug. Method of measurement: FSFI questionnaire.;Satisfaction. Timepoint: At the beginning of the study, 7days after it and 1 month after finishing the drug. Method of measurement: FSFI questionnaire.;Orgasm. Timepoint: At the beginning of the study, 7 days after it and 1 month after finishing the drug. Method of measurement: FSFI questionnaire.;Dysparonia. Timepoint: At the beginning of the study, 7 days after it and 1 month after finishing the drug. Method of measurement: FSFI questonnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Akhtari

Traditional Medicine Faculty of Tehran Medical Colledge

elham_akhtari@yahoo.com; e-akhtari@tums.ac.ir+98 21 2610 1305

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026